Zacks Small Cap Weighs in on IN8bio, Inc.’s Q3 2024 Earnings (NASDAQ:INAB)

IN8bio, Inc. (NASDAQ:INAB) – Equities research analysts at Zacks Small Cap lifted their Q3 2024 EPS estimates for shares of IN8bio in a report issued on Wednesday, August 14th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.14) for the quarter, up from their prior forecast of ($0.15). The consensus estimate for IN8bio’s current full-year earnings is ($0.60) per share. Zacks Small Cap also issued estimates for IN8bio’s FY2024 earnings at ($0.65) EPS and FY2025 earnings at ($0.68) EPS.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03).

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.50 target price on shares of IN8bio in a report on Friday, June 14th.

IN8bio Stock Performance

Shares of INAB opened at $0.53 on Monday. The firm has a 50-day moving average of $0.84 and a 200-day moving average of $1.02. IN8bio has a one year low of $0.50 and a one year high of $2.48. The company has a market cap of $23.28 million, a PE ratio of -0.58 and a beta of 0.06. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.10 and a quick ratio of 4.10.

Institutional Trading of IN8bio

An institutional investor recently bought a new position in IN8bio stock. AIGH Capital Management LLC acquired a new position in IN8bio, Inc. (NASDAQ:INAB) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 4,098,361 shares of the company’s stock, valued at approximately $5,216,000. IN8bio makes up approximately 2.1% of AIGH Capital Management LLC’s investment portfolio, making the stock its 20th biggest position. AIGH Capital Management LLC owned 12.81% of IN8bio at the end of the most recent reporting period. Institutional investors and hedge funds own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.